Oncolytics Biotech Inc. (ONCY) has a negative trailing P/E of -4.4, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 8.0 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -22.79%, forward earnings yield 12.50%. PEG 0.02 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 35/100 with 1/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -2.2 | -0.65 | 3.17 | 0.00 | - |
| 2017 | -6.0 | 0.90 | 11.26 | 0.00 | - |
| 2018 | -2.3 | 0.43 | 6.39 | 0.00 | - |
| 2019 | -3.0 | -0.03 | -1,267.26 | 0.00 | - |
| 2020 | -7.3 | 0.10 | 4.95 | 0.00 | - |
| 2021 | -4.5 | -2.15 | 2.60 | 0.00 | - |
| 2022 | -6.7 | 0.55 | 4.83 | 0.00 | - |
| 2023 | -5.7 | 1.24 | 4.29 | 0.00 | - |
| 2024 | -3.2 | 0.00 | 16.80 | 0.00 | - |
| 2025 | -2.9 | 0.11 | -22.05 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-1.20 | $0.00 | $-15.14M | - |
| 2017 | $-1.12 | $0.00 | $-15.62M | - |
| 2018 | $-1.06 | $0.00 | $-17.04M | - |
| 2019 | $-2.06 | $0.00 | $-45.55M | - |
| 2020 | $-0.48 | $0.00 | $-19.55M | - |
| 2021 | $-0.49 | $0.00 | $-26.3M | - |
| 2022 | $-0.43 | $0.00 | $-24.84M | - |
| 2023 | $-0.41 | $0.00 | $-27.75M | - |
| 2024 | $-0.41 | $0.00 | $-31.71M | - |
| 2025 | $-0.30 | $0.00 | $-28.76M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.31 | $-0.32 – $-0.29 | $1.19M | $1.18M – $1.19M | 3 |
| 2027 | $-0.28 | $-0.29 – $-0.26 | $1.18M | $1.18M – $1.18M | 2 |
| 2028 | $-0.28 | $-0.28 – $-0.28 | $5.57M | $5.57M – $5.57M | 1 |
| 2029 | $-0.19 | $-0.19 – $-0.19 | $69.7M | $69.7M – $69.7M | 1 |
| 2030 | $0.58 | $0.58 – $0.58 | $225.43M | $225.43M – $225.43M | 1 |
